Gibson DC, et al. - Using data from a large nationally representative commercial health insurance program from 2009 to 2017, researchers assessed shifts in patterns of opioid prescribing in surgical breast cancer patients, given concerns regarding suboptimal pain management for actively managed cancer patients after the 2014 federal reclassification of hydrocodone. Women, aged 18 years and older, with carcinoma in-situ or malignant breast cancer treated with breast-conserving surgery or mastectomy from 2010 to 2016 were identified. In this study including 60,080 patients, the findings revealed less chance of receipt of short- and long-term opioid prescriptions in surgically treated breast cancer patients after the implementation of hydrocodone rescheduling.